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INTRODUCTION:  Denosumab  is  a  monoclonal  RANKL  antibody  which  has  been  shown  to  be  highly  effective
in treating  giant  cell  tumour  (GCT)  of  bone.  We  report  on its  use as  a neo-adjuvant  agent  to  avoid  morbid
surgery  for an adolescent.
PRESENTATION  OF  CASE:  We  report  a case  of  a15-year  old  female  with  a Campanacci  3 GCT involving the
femoral  head  and  neck.
DISCUSSION:  To  preserve  bone  stock  and  avoid  an outright  hip  replacement,  the  patient  was given  deno-
sumab  pre-operatively  to consolidate  the  tumour.  After  receiving  6 months  of treatment,  a rim  of cortical
bone  had  developed  to  allow  an  extended  curettage  of the  tumour  to be performed  without  fear  ofCT
emoral head
ip
enosumab
collapse  of  the  articular  surface.
CONCLUSION:  This  is  the ﬁrst  reported  case  of  the  use of denosumab  in  GCT  of  the  femoral  head  and  neck.
We  describe  our  experience  in the  neo-adjuvant  use of denosumab  and  offer  suggestions  for  future  use.
Further  studies  will  be  needed  to see  if denosumab  has  a  role  in  conventional  GCT  and  whether  it can
lead  to a lowering  of  local  recurrence  rates.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Receptor activator of nuclear factor kappa-B ligand (RANKL)
rives osteoclast formation, function and survival and an excess of
ANKL causes an increase in bone destruction. In giant cell tumour
f bone (GCT) RANKL is secreted by neoplastic ovoid cells as well as
onocytoid cells and drives the formation of RANK positive non-
eoplastic osteoclast like cells, which mediate bone destruction in
CT.1,2
Denosumab is a human monoclonal RANKL antibody currently
icenced in the UK for the treatment of resistant osteoporosis and
etastatic bone disease.3,4 By disruption of RANK–RANKL interac-
ion denosumab inhibits osteoclast mediated bone destruction in
his osteolytic bone tumour. It has also been shown to be highly
ffective in giant cell tumours (GCT), with a 96% response rate
ecently reported in a Phase 2 clinical trial when used in patients
ith either inoperable GCT or where surgery would be associated
ith major morbidity.5,6 In the reported trial, 90% of patients who
ere planned to have major surgery and who received denosumab
ither avoided surgery or had less morbid surgery. As a result of
his trial denosumab was approved for use in the USA for unre-
ectable GCT or where surgical resection was likely to result in
evere morbidity by the FDA in June 2013.7
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Denosumab is given monthly by subcutaneous injections of
120 mg  and the principal side effects include osteonecrosis of the
jaw and hypocalcamia.6 It is contraindicated in anyone with pre-
existing dental sepsis or hypocalcaemia and in children who  are
still growing. Any female of child bearing age must use appropri-
ate contraception as denosumab crosses the placental membrane
and has been associated with increase stillbirth and decreased
growth/development in infants in animal studies.8 There is evi-
dence that if denosumab is stopped without the lesion being
surgically removed, that recurrence is probably inevitable (per-
sonal communication). This may mean that in inoperable tumours
denosumab will need to be continued indeﬁnitely.
We  report on the use of densoumab in a 15 year old female to
demonstrate how less morbid surgery can be performed using this
as a neoadjuvant agent. The report was prepared in accordance with
ethical standards and written informed consent was obtained.
2. Presentation of case
A 15 years old female presented with progressive left groin pain
and difﬁculty in walking. Plain radiographs showed a lytic lesion
involving the left femoral head and neck (Fig. 1). MRI  scans demon-
strate the involvement of >50% of the head and neck of the femur
with a cortical breach. CT-guided biopsy showed the typical appear-
ance of a giant cell tumour of bone rich in osteoclast-like giant
cells scattered within densely packed plump to slightly spindled
mononuclear cells (Fig. 4A). The CT also demonstrated the almost
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. (A) Plain AP radiograph of the pelvis showing a giant cell tumour of bone within the left femoral head and neck (arrow). (B) T1-weighted MRI  scan demonstrating the
extent of the tumour within the femoral head and neck and corresponding cortical breach (arrow).
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dig. 2. Serial radiographs showing response to treatment with denosumab. (A) Rad
f  bone around the head and neck of the left femur. (B) Further ossiﬁcation of the fe
omplete absence of any bone supporting the articular surface. An
xtended curettage, even with grafting, would lead to almost cer-
ain collapse of the femoral head given the extent of the tumour and
eave no other option for reconstruction other than a hip replace-
ent. To avoid an outright joint replacement in a teenager, we
pted to give denosumab, to see if this would consolidate the
umour and the surrounding bone.
After obtaining informed written consent, denosumab was
pproved for use in this case by the host institution and was  given
20 mg  subcutaneously monthly for 6 months with additional
oses at day 8 and 15 of the ﬁrst month as previously described.6
alcium and vitamin D supplementation was provided with regular
onitoring for signs of hypocalcemia and osteonecrosis. Within six
eeks her hip symptoms resolved and the patient was pain free.
erial radiographs and CT showed the development of a good rim
f cortical bone with clinical improvement in pain and ability to
alk (Fig. 2).
After six months of denosumab, the patient underwent an
xtended curettage of her femoral head. Through a lateral approach
o the hip, a cortical window was made over the lateral cortex to
llow access to the femoral head and neck as previously described.9
he curettage was performed with various angled curettes and a
igh-speed burr under image intensiﬁer control to map out the
xtent of the tumour and ensure a complete curettage (Fig. 3). An
psilateral ﬁbular graft was harvested and placed as a strut sup-
orting the articular surface and the remainer of the cavity packed
ith femoral head autograft.
Curettings taken following denosumab treatment showed
triking morphological changes to classical GCT appearances as
escribed previously.10 The majority of the tumour area washs after 6 weeks of starting denosumab illustrating reformation of the cortical rim
l head and neck after 6 months of treatment.
occupied by long spindle cells with bland nuclei within a densely
collagenised matrix (Fig. 4C). There were cellular nodules of resid-
ual mononuclear cells also with smaller nuclei with condensed
chromatin (Fig. 4B). Residual osteoclast-like giant cells were not
found. Newly formed woven bone was  also seen (Fig. 4D).
3. Discussion
Giant cell tumours of the femoral head and neck are rare lesions
that often present a surgical dilemma to the treating orthopaedic
oncologist. Although intralesional curettage is the standard treat-
ment for Campanacci 1 and 2 tumours of femoral head and
neck,11–13 this treatment strategy is often not possible in Cam-
panacci 3 tumours. Due to limited bone stock and high rates of local
recurrence, primary excision and reconstruction with a hip artho-
plasty or endoprosthetic replacement has been advocated. Khan
et al. reported on 12 patients with Campanacci 3 GCT of the prox-
imal femur which were adequately treated with endoprosthetic
replacements without local recurrences.14 Tibrewal reported on
four cases treated primarily with curettage, all developing local
recurrence, and suggested the possibility of hip arthroplasty as pri-
mary treatment.15 Given the patient’s young age, avoidance of a
joint replacement is of utmost importance, especially in the setting
of a benign neoplasm.
The decision to use denosumab was  based on the senior
author’s experience of contributing patients to the Phase 2 trial
and the observation that denosumab produces a rim of ﬁrm bone
around a residual central cavity at the site of the tumour. Max-
imal radiological response is usually seen within 26 weeks. In
some cases there is complete consolidation of the previous GCT
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Fig. 3. (A) Curettage performed under intra-operative radiographs. (B) Post-operative radiograph showing curetted cavity with ﬁbular strut graft in place.
Fig. 4. (A) Pre-treatment biopsy specimen showing typical features of primary giant cell tumour of bone: scattered osteoclast-like giant cells amidst uniform plump mono-
n nosum
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cuclear cells, haematoxylin eosin (H/E), original magniﬁcation (OM) 200×; (B) de
ensely  collagenised matrix, HE (OM 100×). (C) Residual focus of plump mononuc
one  within curetting, HE (OM 100×).
ut more usually a ‘neocortex’ reforms giving structural sup-
ort.
This however is the cause of a dilemma in then manag-
ng the GCT surgically. Consolidation with denosumab treatment
enders GCT less deﬁned macroscopically and microscopically
aking the decision of the extent of surgical excision more dif-
cult. Branstetter and co-workers have suggested that neoplastic
ells in GCT undergo differentiation into mature bone.10 This is
ifﬁcult to distinguish from physiological or reparative woven
one deposition. Although the ‘centre’ has been cleaned out, will
here still be residual tumour cells in the ‘neocortex’ which will
ecome active again once the denosumab is stopped? This ques-
ion remains to be answered by longer term follow up of the trial
ohort.6ab treated GCT showed elongated bland spindle cells with small nuclei within a
ells devoid of osteoclast-like giant cells HE (OM 100×). (D) Newly formed woven
Another question which remains to be answered is the duration
of treatment and also the frequency of dosing in patients on long
term denosumab. The trial patients continue to receive monthly
injections either until they relapse (which has occurred in 4%) or
they undergo deﬁnitive surgery. It remains to be seen if the relapse
rate will increase with time and if ‘drug resistance’ will start to
emerge. Stopping the drug may  be an attractive option, particularly
in young females, who are advised to have a 7 month time off the
drug before becoming pregnant. It remains to be seen whether this
will lead to relapses during this time period.The true role of denosumab has yet to be established. Further
studies will be needed to see if it has a role in conventional GCT
and whether it can lead to a lowering of local recurrence rates. For
the time being, it is not licenced for use in GCTs in the UK or Europe
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ut it can certainly produce dramatic results in patients who would
therwise face disabling surgical procedures or in whom all other
reatment options have failed.
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Key learning points
• Denosumab was successfully used as a neoadjuvant agent to avoid outright hip replacement for an adolescent with
Campanacci 3 GCT of the femoral head and neck.
• Further studies and follow-up is required to determine role of denosumab in surgically treated GCT.
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